An observational study in Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 and Maturity-onset Diabetes of the Young, sponsored by Imperial College London Diabetes Centre. Status unknown at 1 site in United Arab Emirates. Per ClinicalTrials.gov, last updated 2020-08-19.
Sponsored by Imperial College London Diabetes Centre · Observational
The study aims to investigate the validity of 2 hour post-prandial UCPCR test in paediatric and adult patients with diabetes duration greater than 2 and 5 years, respectively, for the purposes of distinguishing between patients with type 1 diabetes and MODY in the UAE population.
Urinary C-peptide creatinine ratio (UCPCR) is a non invasive measure of endogenous insulin secretion and has been shown to be effective in identifying Maturity Onset Diabetes of the Young (MODY) from Type 1 Diabetes in adults and paediatric population. Here in the UAE, diabetes prevalence is at 18.9% of the general population and patients are medically treated according to their diabetes type. Currently identification of patients with MODY poses multiple challenges and in some instances results in wrongful diagnosis and treatment of the patients. Most commonly, patients are treated as having type 1 diabetes and given unnecessary insulin injections.
Making correct diabetes diagnosis is pivotal for appropriate disease management. Currently, a set of criteria including age of onset of diabetes (\<30 years), BMI\<25kg/m2 and absence of islet-cell and GAD auto-antibodies are applied in order to identify potential Maturity Onset Diabetes of the Young (MODY) patients. This has to be followed by genetic testing before final diagnosis is made. Although the set criteria increase the probability of identifying MODY patients, fully discriminating between MODY and type 1 diabetes can still be difficult. As such, some MODY patients (e.g. with mutations in HNF1A or HNF4A genes) are wrongfully treated with insulin when sulphonylureas would be efficient enough for management of their diabetes.
This study will consists of three groups; patients who are autoantibody negative (divided into patients with potential MODY and patients with type 2 diabetes), patients diagnosed with type 1 diabetes and patients who do not have diabetes at the time of recruitment (selected randomly and will include patients with other diagnoses such as IFG and/or IGT). All groups will consist of paediatric patients (≤18 years of age) and adult patients (age of onset of diabetes ≤ 30 years).
The scientific aims of the study are:
10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.
This study's planned enrollment of 778 is above the median of 233 across 2,220 observational studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →Imperial College London Diabetes Centre is the lead sponsor of 13 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients attending Imperial College London Diabetes Centre, UAE.
Exclusion Criteria:
Patients who are autoantibody negative (could potentially be either MODY or type 2 diabetes patients) Suspected MODY patients will be candidates for next generation sequencing (NGS)
Genetic: Next generation sequencing (NGS)
Patients diagnosed with type 1 diabetes mellitus Patients with positive UCPCR and negative autoantibodies results will be suspected with MODY and will be candidates for next generation sequencing (NGS)
Genetic: Next generation sequencing (NGS)
Individuals not diagnosed with any type of diabetes (but could be diagnosed with IFG and/or IGT)
Patients will be tested for known MODY genes with specific focus on HNF1A, GCK and HNF4A genes. Furthermore, gene panel testing may be performed for any known diabetes genes.If the results are negative, WES/WGS will be performed in patients suspected of having MODY for identification of novel MODY mutations.
Also known as: NGS panel, Whole exome/genome sequencing (WES/WGS)
Urinary C-peptide Creatinine Ratio (UCPCR)
Measuring UCPCR in our study cohort and testing if a cutoff of 0.7nmol/mmol in children and 0.2nmol/mmol in adults will apply to our population of interest (ie UAE population).
Time frame: 2 hours post-prandial
Receiver operating characteristic (ROC) curve
Using receiver operating characteristic (ROC) curves to identify the optimal UCPCR cut-off for discriminating diabetes subtypes in our study population.
Time frame: through study completion, an average of 1 year
Genetic analysis
Confirming our UCPCR results through genetic analysis of the samples.
Time frame: through study completion, an average of 2 year
Positive genetic result analysis
Validating positive genetic test results by performing mutational analysis on the parents of the patient.
Time frame: through study completion, an average of 2 year
Novel MODY genes and mutations
Identifying novel MODY genes and/or mutations in the study population through next generation sequencing methodologies
Time frame: through study completion, an average of 2 year
UCPCR measurements
Conducting UCPCR measurements for patients who have been clinically and genetically diagnosed with MODY. This will assist us in confirming the cutoff values for MODY diagnosis.
Time frame: through study completion, an average of 2 year
Prevalence of MODY
Estimating the background prevalence of MODY in diabetes patients in the Emirates of Abu Dhabi.
Time frame: through study completion, an average of 2 year
This study is status unknown, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Imperial College London Diabetes Centre